Potential of First-in-Class Epidiolex for Epilepsy and its Significance in the Advent of Medical Marijuana
Potential of First-in-Class
Epidiolex for Epilepsy and its
Significance in the Advent
of Medical Marijuana
Ομόφωνη έγκριση από τη γενική συνέλευση της MIG για την πώληση του Υγεία
Εγκρίθηκε από τη συντριπτική πλειοψηφία (95,7%) στην τακτική γενική συνέλευση των μετόχων της MIG η πώληση του ποσοστού της στο Υγεία (70,38%) στη Hellenic Healthcare, θυγατρική του fund CVC. Στη … Continue Reading Ομόφωνη έγκριση από τη γενική συνέλευση της MIG για την πώληση του Υγεία
Εντυπωσιακή αύξηση τζίρου από τις εξαγωγές για τη φαρμακοβιομηχανία
Υπερδιπλασιασμό της εξαγωγικής δραστηριότητας στα χρόνια της κρίσης εμφανίζει η εγχώρια φαρμακευτική βιομηχανία. Σύμφωνα με τα πρόσφατα στοιχεία της ΕΛΣΤΑΤ, ο κύκλος εργασιών (εγχώρια αγορά και εξαγωγές) στη φαρμακευτική βιομηχανία σημείωσε αύξηση 11,5% την … Continue Reading Εντυπωσιακή αύξηση τζίρου από τις εξαγωγές για τη φαρμακοβιομηχανία
Vantage Pharma, Biotech & Medtech Half-Year Review 2018
The Vantage Half-Year Review 2018 shows that biopharma small drug developers continue to hold all the cards, while young device makers suffer from a shrinking pool of buyers. Our report … Continue Reading Vantage Pharma, Biotech & Medtech Half-Year Review 2018
Q3 2018 Outlook Report
Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and … Continue Reading Q3 2018 Outlook Report
Innovations in Oncology: The Cancer Moonshot and Beyond [eBook]
This eBook is a celebration of the innovative efforts driving cancer research forward. Download this eBook to: Discover the diverse and innovative projects propelling the Cancer Moonshot forward Read thought-provoking … Continue Reading Innovations in Oncology: The Cancer Moonshot and Beyond [eBook]
Brexit Implications for Pharma Article Pack
Discover why Brexit Won’t Delay Drug Approvals. Plus how the #UK & the #EuropeanMedicinesAgency could work together informally after #Brexit. Download the full article pack & learn more: Brexit Implications for Pharma Article Pack V2 … Continue Reading Brexit Implications for Pharma Article Pack
2017 Completed Trials report
Status Quo or No? As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were … Continue Reading 2017 Completed Trials report
Pharma Asset Insights report
Innovation in the pharmaceutical industry has never been more exciting, and complicated. Disruptive technologies, such as artificial intelligence and digital health tools, and advanced therapeutic modalities including cell and gene … Continue Reading Pharma Asset Insights report
Clinical Genomics 101: 2018 Edition
The last twelve months have seen many advances within the field of genomics. The price of sequencing and analysis has continued to drop dramatically and accuracy gets better with … Continue Reading Clinical Genomics 101: 2018 Edition
Cancer Genomics 101: 2018 Edition
Cancer is one of the oldest diseases known to human society, and recently it’s the development of next-generation sequencing and a stronger understanding of genetic mutations that have driven … Continue Reading Cancer Genomics 101: 2018 Edition
Drug Development 101: 2018 Edition
Developing new drugs isn’t easy. Only around 10% of compounds that reach preclinical development will ever be tested in a human being and for every drug that reaches the … Continue Reading Drug Development 101: 2018 Edition
«Καμπανάκι» για τις εταιρίες βιοεπιστημών
Οι εταιρείες βιοεπιστημών κινδυνεύουν να περιθωριοποιηθούν από τις εταιρείες τεχνολογίας και τους νεοεισερχόμενους στην αγορά παίκτες, σύμφωνα με τη νέα έκθεση της EY, Progressions 2018 Life Sciences 4.0: Securing value through data–driven platforms. Η έκθεση αναφέρει ότι … Continue Reading «Καμπανάκι» για τις εταιρίες βιοεπιστημών
Cell and Gene Therapies 2018 – State Of The Industry Report
b324212e-f8ed-4534-8faf-21cfd83cedc2_KNect365CellandGeneTherapiesReport2018 Πηγή
EVALUATEPHARMA ORPHAN DRUG REPORT 2018
Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the … Continue Reading EVALUATEPHARMA ORPHAN DRUG REPORT 2018
PIPELINE REPORT Brand Drugs
PipelineReport-Brand-Drugs
